TrialTheranostics2016
[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Richard P Baum et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this paperpooled itcites it